324 related articles for article (PubMed ID: 34237810)
1. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
Eklund M; Jäderling F; Discacciati A; Bergman M; Annerstedt M; Aly M; Glaessgen A; Carlsson S; Grönberg H; Nordström T;
N Engl J Med; 2021 Sep; 385(10):908-920. PubMed ID: 34237810
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
3. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
4. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
Kasivisvanathan V; Rannikko AS; Borghi M; Panebianco V; Mynderse LA; Vaarala MH; Briganti A; Budäus L; Hellawell G; Hindley RG; Roobol MJ; Eggener S; Ghei M; Villers A; Bladou F; Villeirs GM; Virdi J; Boxler S; Robert G; Singh PB; Venderink W; Hadaschik BA; Ruffion A; Hu JC; Margolis D; Crouzet S; Klotz L; Taneja SS; Pinto P; Gill I; Allen C; Giganti F; Freeman A; Morris S; Punwani S; Williams NR; Brew-Graves C; Deeks J; Takwoingi Y; Emberton M; Moore CM;
N Engl J Med; 2018 May; 378(19):1767-1777. PubMed ID: 29552975
[TBL] [Abstract][Full Text] [Related]
5. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
Hugosson J; Månsson M; Wallström J; Axcrona U; Carlsson SV; Egevad L; Geterud K; Khatami A; Kohestani K; Pihl CG; Socratous A; Stranne J; Godtman RA; Hellström M;
N Engl J Med; 2022 Dec; 387(23):2126-2137. PubMed ID: 36477032
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
[TBL] [Abstract][Full Text] [Related]
8. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
[TBL] [Abstract][Full Text] [Related]
9. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
Ahdoot M; Wilbur AR; Reese SE; Lebastchi AH; Mehralivand S; Gomella PT; Bloom J; Gurram S; Siddiqui M; Pinsky P; Parnes H; Linehan WM; Merino M; Choyke PL; Shih JH; Turkbey B; Wood BJ; Pinto PA
N Engl J Med; 2020 Mar; 382(10):917-928. PubMed ID: 32130814
[TBL] [Abstract][Full Text] [Related]
10. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
[TBL] [Abstract][Full Text] [Related]
11. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
12. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
13. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
[TBL] [Abstract][Full Text] [Related]
14. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
15. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
Lee DH; Nam JK; Park SW; Lee SS; Han JY; Lee SD; Lee JW; Chung MK
Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553
[TBL] [Abstract][Full Text] [Related]
16. Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.
Shakir NA; George AK; Siddiqui MM; Rothwax JT; Rais-Bahrami S; Stamatakis L; Su D; Okoro C; Raskolnikov D; Walton-Diaz A; Simon R; Turkbey B; Choyke PL; Merino MJ; Wood BJ; Pinto PA
J Urol; 2014 Dec; 192(6):1642-8. PubMed ID: 25117476
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
18. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
[TBL] [Abstract][Full Text] [Related]
19. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.
Drost FH; Osses D; Nieboer D; Bangma CH; Steyerberg EW; Roobol MJ; Schoots IG
Eur Urol; 2020 Jan; 77(1):78-94. PubMed ID: 31326219
[TBL] [Abstract][Full Text] [Related]
20. Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naïve men.
Knaapila J; Autio V; Jambor I; Ettala O; Verho J; Kiviniemi A; Taimen P; Perez IM; Aronen HJ; Syvänen KT; Boström PJ
Scand J Urol; 2020 Feb; 54(1):7-13. PubMed ID: 31914846
[No Abstract] [Full Text] [Related]
[Next] [New Search]
